PUBBLICAZIONI
26. Vergati M, Krasniqi E, Del Monte G, Riondino S, Vallone D, Guadagni F, Ferroni P, Roselli M.
Ketogenic diet and other dietary intervention strategies in the treatment of cancer.
Curr Med Chem. 2017 Jan 16. [Epub ahead of print]. IF: 3,85
Venous
thromboembolism risk prediction in ambulatory cancer patients: Clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte
ratio.
Int J Cancer. 2015 Mar
1;136(5):1234-40. IF: 5,44
24. Ferroni P, Guadagni
F, Laudisi A, Vergati M, Riondino S, Russo A, Davì G, Roselli M.
Estimated
glomerular filtration rate is an easy predictor of venous thromboembolism in cancer patients undergoing platinum-based chemotherapy.
Oncologist. 2014
May;19(5):562-7. IF: 4,54
23. Jochems C, Tucker
JA, Vergati M, Boyerinas B, Gulley JL, Schlom J, Tsang KY.
Identification and
characterization of agonist epitopes of the MUC1-C oncoprotein.
Cancer Immunol
Immunother. 2014 Feb;63(2):161-74. IF: 3,80
22. Madan RA, Tsang KY,
Bilusic M, Vergati M, Poole DJ, Jochems C, Tucker JA, Schlom J, Giaccone G, Gulley JL.
Effect of talactoferrin
alfa on the immune system in adults with non-small cell lung cancer.
Oncologist.
2013;18(7):821-2. IF: 4,54
21. Vergati
M, Della-Morte D, Ferroni P, Cereda V, Tosetto L, La Farina F, Guadagni F, Roselli M.
Increased risk of
chemotherapy-associated venous thromboembolism in elderly patients with cancer.
Rejuvenation Res. 2013
Mar 22; IF: 3,83
20. Roselli M, Ferroni
P, Riondino S, Mariotti S, Laudisi A, Vergati M, Cavaliere F, Palmirotta R, Guadagni F.
Impact of chemotherapy
on activated protein C-dependent thrombin generation-Association with VTE occurrence.
Int J Cancer. 2013 Feb
12; IF: 5,44
19. Huen
NY, Pang AL, Tucker JA, Lee TL, Vergati M, Jochems C, Intrivici C, Cereda V, Chan WY, Rennert OM, Madan RA, Gulley JL, Schlom J, Tsang
KY.
Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer.
Int J Cancer. 2013 Jan
15; IF: 5,44
18. Vergati
M, Filingeri V, Palmieri G, Roselli M.
Perianal Paget’s
disease: a case report and literature review.
Anticancer Res. 2012
Oct; 32(10): 4461-5. IF: 1,41
17. Roselli M, Ferroni
P, Portarena I, Riondino S, La Farina F, Formica V, Vergati M, Guadagni F.
Predictive
value of high-sensitive D-dimer determination for chemotherapy-associated venous thromboembolism in gastrointestinal cancer patients.
Thromb Haemost. 2012 Oct
10; 108(6): 1243-5. IF: 5,04
16. Madan
RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JL, Dahut WL, Schlom J, Gulley
JL.
A phase I
trial of ipilimumab and a poxviral vaccine targeting PSA in metastatic castration-resistant prostate cancer: analysis of toxicity, response, and
survival.
Lancet Oncol. 2012 May;
13(5): 501-8. IF: 17,76
15. Cereda V,
Vergati M, Huen NY, di Bari MG, Gulley JL, Apelian D, Schlom J, Tsang KY.
Maturation
of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces number and function of regulatory T cells and enhances the ratio of antigen-specific
effectors to regulatory T cells.
Vaccine. 2011 Jul 12;
29(31): 4992-9. IF: 3,62
14. Vergati
M, Schlom J, Tsang KY.
The
consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring. Review.
J Biomed Biotechnol.
2011: 182413. IF: 1,75
13. Vergati
M, Cereda V, Madan RA, Gulley JL, Huen NY, Rogers CJ, Hance KW, Arlen PM, Schlom J, Tsang KY.
Analysis of circulating
regulatory T-cells in patients with metastatic prostate cancer pre- versus post-vaccination.
Cancer Immunol
Immunother. 2011 Feb; 60(2): 197-206. IF: 3,80
12. Vergati
M, Intrivici C, Huen NY, Schlom J, Tsang KY.
Strategies for Cancer
Vaccine Development. Review.
J Biomed Biotechnol.
Volume 2010 (2010), Article ID 596432. IF: 1,75
11. Gulley JL, Arlen PM,
Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL,
Schlom J.
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant
prostate cancer.
Cancer Immunol
Immunother. 2010 May; 59(5): 663-74. IF: 3,80
10. Graziani G, Tentori
L, Muzi A, Vergati M, Tringali G, Pozzoli G, Navarra P.
Evidence
that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype.
Mol Cell Endocrinol.
2007 Jan 29; 264 (1-2): 44-9. IF: 2,79
9. Tentori
L, Leonetti C, Scarsella M, Muzi A, Mazzon E, Vergati M, Forini O, Lapidus R, Xu W, Dorio AS, Zhang J, Cuzzocrea S, Graziani
G.
Inhibition
of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon
carcinoma.
FASEB J. 2006 Aug;
20(10): 1709-11. IF: 7,06
8. Graziani G,
Ferrandina G, Pozzoli G, Vergati M, Muzi A, Legge F, Tentori L, Scambia G, Navarra P.
Corticotropin-releasing
hormone receptor-1 in human endometrial cancer.
Oncol Rep. 2006 Feb;
15(2): 375-9. IF: 1,57
7. Tentori L, Leonetti
C, Scarsella M, Muzi A, Vergati M, Forini O, Lacal PM, Ruffini F, Gold B, Li W, Zhang J, Graziani G.
Poly(ADP-ribose)
glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
Eur J Cancer 2005 Dec;
41(18): 2948-57. IF: 3,71
6. Vergati
M, Tentori L, Muzi A, Levati L, Ruffini F, Forini O, Vernole P, Lacal PM, Graziani G.
Generation
of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer
drugs.
Int J Oncol. 2005 Aug;
27(2): 525-536. IF: 2,54
5. Tentori
L, Leonetti C, Scarsella M, Vergati M, Xu W, Calvin D, Morgan L, Tang Z, Woznizk K, Alemu C, Hoover R, Lapidus R, Zhang J, Graziani
G.
Brain
distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS
tumors.
Int J Oncol. 2005 Feb;
26(2): 415-22. IF: 2,54
4. Tentori L, Forini O,
Fossile E, Muzi A, Vergati M, Portarena I, Amici C, Gold B, Graziani G.
N3-methyladenine induces early poly(ADP-ribosylation), reduction of nuclear factor-kappa B DNA binding ability, and nuclear upregulation of
telomerase activity.
Mol Pharmacol. 2005
Feb;67(2):572-81. IF: 5.29
3. Tentori L, Leonetti
C, Scarsella M, D’Amati G, Vergati M, Portarena I, Xu W, Kalish V, Zupi G, Zhang J, Graziani G.
Systemic
administration of GPI 15427, a novel poly(ADP-Ribose)Polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma,
glioma, lymphoma.
Clin Cancer Res. 2003
Nov; 9(14): 5370-9. IF: 5,07
2. Graziani G, Tentori
L, Portarena I, Vergati M, Navarra P.
Valproic acid increases
the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells.
Endocrinology 2003 Jul;
144(7): 2822-8. IF: 4.97
1. Tentori L, Portarena
I, Barbarino M, Balduzzi A, Levati L, Vergati M, Biroccio A, Gold B, Lombardi ML, Graziani G.
Inhibition
of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (ADP-ribose) polymerase
inhibitor.
Mol Pharmacol. 2003 Jan;
63(1):192-202. IF: 5.29
ABSTRACTS, POSTERS E PRESENTAZIONI ORALI
18. Rossi P, Montuori M, Ricciardi E, De Sanctis F, Vergati M, Roselli M, Ricozzi I, Campione E, Chimenti S, Petrella G.
Electrochemotherapy in the treatment of cutaneous and subcutaneous neoplasms.
EJSO. 2012 Oct; 38(10): 1003-4. IF: 2,49
17. Tsang KY, Vergati M, Jochems C, Madan RA, Gulley JL, Schlom J.
Circulating regulatory T-cell function and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients
treated with vaccine.
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA (USA), November
12-16, 2011.
16. Heery C, Pinto PA, Schlom J, Tsang KY, Madan RA, Poole D, Vergati M, Walter Rodriguez B, Merino M, Gulley JL.
Intraprostatic vaccine administration in patients with locally recurrent prostate cancer.
Journal of Clinical Oncology, 2011 ASCO Genitourinary Cancers Symposium: 72435.
15. Madan RA, Mohebtash M, Arlen PM, Vergati M, Steinberg SM, Tsang KY, Dahut WL, Schlom J, Gulley JL.
Overall survival (OS) analysis of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment
of metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology, 2010 ASCO Annual Meeting: 51902.
14. Cereda V, Vergati M, Huen NY, di Bari MG, Gulley JL, Franzusoff A, Schlom J, Tsang KY.
Treatment of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces number and function of regulatory T cells
(Tregs) and enhances the ratio of antigen-specific effectors to Tregs.
AACR 101st Annual Meeting, Washington DC (USA), April 17-21, 2010.
13. Vergati M, Cereda V, Madan RA, Huen NY, Rogers C, Hance K, Gulley JL, Arlen PM, Schlom J, Tsang KY.
Circulating regulatory T-cell function and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients
treated with poxviral-based vaccine.
Oral Abstract Presentation at the International Society for Biological Therapy of Cancer (iSBTc) 24th Annual Meeting,
Washington DC (USA), October 29-31, 2009.
12. Mohebtash M, Madan RA, Arlen PM, Rauckhorst M, Tsang KY, Cereda V, Vergati M, Poole DJ, Dahut WL, Schlom J, Gulley JL.
Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic
castrationresistant prostate cancer (mCRPC).
Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 27, No 15S (May 20 Supplement), 2009: 5144.
11. Cereda V, Vergati M, Madan RA, Arlen PM, Dahut WL, Mohebtash M, Schlom J, Gulley JL, Tsang KY.
Regulatory T-cell (Tregs) function and overall survival in metastatic castration resistant prostate cancer (mCRPC) patients
treated with a vector-based vaccine.
Keystone Symposia on Molecular and Cellular Biology - Regulatory T Cells - Keystone CO (USA), March 1-6, 2009.
10. Ferroni P, Palmirotta R, Martini F, Ludovici G, Magnapera A, Rossi L, Vergati M, Formica V, Roselli M, Guadagni F.
Determinants of homocysteine levels in colorectal and breast cancer patients.
Thrombosis Research, Vol 120; Supplement 2, Pages S146, 2007.
Poster at the 4th International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo (Italy), October 26-28, 2007.
9. Zhang J, Tentori L, Leonetti C, Scarsella M, Muzi A, Mazzon E, Vergati M, Forini O, Lapidus RG, Xu W, Cuzzocrea S, Graziani G.
Oral administration of poly(ADP-ribose) polymerase inhibitor prevents intestinal damage induced by irinotecan and enhances the
efficacy of irinotecan and temozolomide combination against colon carcinoma.
Proc Amer Assoc Cancer Res, Volume 47, 2006. Abstract 2424.
8. Tentori L, Leonetti C, Scarsella M, Vergati M, Muzi A, Forini O, Xu W, Zhang J, Graziani G.
Oral administration of the PARP-1 inhibitor GPI 15427 increases the anti-tumor activity of irinotecan and temozolomide
combination against colon carcinoma.
14th International meeting on ADP ribosylation reactions, “PARP 2005: Bench to Bedside”, Gateshead (UK), October 5-7, 2005.
7. Lapidus RG, Tentori L, Graziani G, Leonetti C, Scarsella M, Vergati M, Muzi A, Zhang J, and the Guilford PARP Project Group.
Oral administration of PARP inhibitor GPI 18180 increases the anti-tumor activity of temozolomide against intracranial melanoma
in mice.
Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No 16S (June 1
Supplement), 2005: 3136.
6. Lacal PM, Ruffini F, Orecchia A, Failla C, Morea V, Soro S, Vergati M, Tentori L, Zambruno G, Graziani G, Tramontano A, D’Atri S.
Inhibition of endothelial cell migration by vascular endothelial growth factor receptor-1 peptides.
Fifth ESH interdisciplinary euroconference on angiogenesis, Sitges (Spain), May 27-30, 2005.
5. Tentori L, Leonetti C, Scarsella M, Vergati M, Muzi A, Xu W, Lapidus R, Zhang J, Graziani G.
Oral administration of the PARP-1 inhibitor GPI 15427 increases the anti-tumor activity of irinotecan against colon carcinoma.
96th Annual meeting American Association for Cancer Research (AACR), Anaheim CA (USA), April 16-20, 2005.
4. Tentori L, Forini O, Muzi A, Vergati M, Gold B, Graziani G.
Role of PARP, NF-kB and telomerase in necrosis induced by selective methylation of N3-adenine.
XVII Italian Congress on the ADP-ribosylation processes, Rome (Italy), December 17-18, 2004.
3. Tentori L, Leonetti C, Scarsella M, D’Amati G, Vergati M, Fossile E, Gold B, Zhang J, Graziani G
Influence of PARP-1 inhibitors on the antitumor activity of methylating agents.
Proceedings of the XVI Italian congress on the ADP-ribosylation processes, Pavia (Italy), September 19-20, 2003.
European Journal of Histochemistry 2003, 47:8 IF: 0,96
2. Graziani G, Tentori L, Portarena I, Preziosi P, Vergati M, Navarra P
Histone deacetylase inhibitors increase the stimulatory effect of estrogens on proliferation of human endometrial cancer cells.
Proceedings of the XIII National congress of the Italian Society of Toxicology, Urbino (Italy), January 22-25, 2003
1. Graziani G, Tentori L, Portarena I, Vergati M, Preziosi P, Navarra P
Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells.
Proceedings of the Belgian society of Fundamental and Clinical Pharmacology, Gent. Belgium November 16th, 2002.
Fundamental and Clinical Pharmacology 2003, 17:272 IF: 1.03